Where tirzepatide comes from — and why its origins matter

The misconception: tirzepatide is derived from a lizard or a natural hormone

A common belief about GLP-1 medicines is that they come from the Gila lizard — a story that is partly true for an earlier drug called exenatide, which was based on a compound found in the lizard's saliva. Tirzepatide is different. It is a wholly synthetic peptide, meaning its molecular structure was designed by chemists at Eli Lilly rather than copied from anything found in nature.

Where it draws biological inspiration is in its function, not its origin. The human body naturally produces two gut hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), both of which are released after eating and play a role in controlling appetite, insulin secretion and gastric emptying. Lilly's scientists studied these hormone structures and engineered tirzepatide to bind to both receptors at once. The molecule itself is novel, a 39-amino-acid peptide that does not appear in nature in this form.

This distinction matters practically. Because tirzepatide is synthetic and precisely engineered, it can be manufactured to a consistent pharmaceutical standard, tested for purity, and quality-controlled at every stage. The BNF monograph for tirzepatide classifies it as a dual GIP and GLP-1 receptor agonist, a category that did not exist in UK medicine before Mounjaro's approval.

So: the idea that these medicines are "natural" is a myth worth correcting. Tirzepatide is a precision-engineered pharmaceutical compound.

From Eli Lilly's laboratories to a UK-licensed medicine

Eli Lilly, the company behind tirzepatide, is one of the oldest pharmaceutical manufacturers in the world, headquartered in Indianapolis. The molecule was developed through Lilly's diabetes and metabolic disease research programme, the same programme that later generated the SURMOUNT clinical trials, which studied tirzepatide specifically for weight management in adults without diabetes.

In the SURMOUNT-1 trial, which randomised 2,539 adults with obesity, participants on the highest dose (15mg) lost around 20–21% of body weight on average over 72 weeks, a result published in the New England Journal of Medicine. Those findings supported the medicine's UK licence for weight management.

For those curious about the broader commercial background, the question of where Mounjaro comes from as a product (including Lilly's authorised UK supply chain) is worth reading alongside this page. Importantly, Mounjaro sold in the UK is manufactured under Lilly's pharmaceutical quality standards and distributed through the licensed UK supply chain. Buying from unverified sellers online carries the serious risk of counterfeit pens, which the MHRA has flagged publicly following large-scale seizures of fake weight-loss injections.

Every Mounjaro pen supplied by a GPhC-registered pharmacy arrives through that authorised chain. There is no shortcut that preserves that guarantee.

Why a synthetic peptide has to be injected, and what that looks like in practice

Because tirzepatide is a peptide (a short chain of amino acids), the digestive system would break it down before it could reach the bloodstream if it were swallowed in conventional tablet form. That is why it is given as a subcutaneous injection (just under the skin) once a week.

The Mounjaro KwikPen is pre-filled and pre-set to the correct dose, so there is no drawing up of liquid or adjusting a dial. Each pen contains four weekly doses. The KwikPen's design is intended to make self-injection straightforward, and most people find the process quicker than they expect. The injection can be given into the abdomen, the front of the thigh or the upper arm; full detail on technique is in the Patient Information Leaflet and on the injection-site guidance page.

After injection, the pen and used needle should be placed in a sharps container, household bins are not suitable for used needles. Storing the pen correctly before use matters too; if you are planning ahead around a holiday or a bank holiday Monday order, it is worth reading the storage guidance in advance, since pens require refrigeration at 2–8°C and the room-temperature window is set out in the SmPC rather than as a fixed rule here.

The NHS patient information for tirzepatide covers how the injection works and what to expect at each dose stage, including common side effects like nausea and loose stools that tend to settle as the body adjusts.

Who can access tirzepatide in the UK, and through which routes

Tirzepatide is licensed in the UK for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. A prescriber assesses the full clinical picture, BMI alone is not the deciding factor, and the medicine is not suitable for everyone.

NICE recommends tirzepatide (TA1026) for NHS use under phased eligibility criteria that have been rolling out since mid-2025. NHS access currently requires a higher BMI and multiple weight-related conditions; criteria are easing in stages through to 2027. For those who do not meet NHS thresholds or prefer not to wait, a private prescription from a regulated online pharmacy is the alternative route. You can verify any online pharmacy on the GPhC register, it takes about thirty seconds.

If you would like to explore whether tirzepatide is clinically appropriate for you, a real clinician reads your consultation answers the same day at nume, not an automated system. The Mounjaro injection overview covers what a treatment course typically involves, and an overview of weight-loss treatment options is a useful starting point if you are weighing up different approaches.